Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nektar Therapeutics has appointed Randall Moreadith as the new senior vice president of drug development and chief development officer effective August 11, 2008. Dr Moreadith will report to president and CEO, Howard Robin.
Subscribe to our email newsletter
Mr Moreadith will lead clinical drug development, clinical pharmacology and toxicology, and regulatory affairs at Nektar. He is responsible for overseeing all aspects of drug development at the company and will drive clinical and regulatory strategy.
Prior to joining Nektar, Mr Moreadith was executive vice president and chief medical officer of Cardium Therapeutics. While at Cardium, he led the advancement of novel DNA-based therapeutics into Phase IIb and Phase III late-stage development.
Mr Robin said: “We are delighted to have someone of Randall’s caliber join the Nektar executive team as we execute on our proprietary drug development strategy.
“Randall is an experienced clinical research and product development executive with an impressive track record of accomplishments. His experience and leadership will allow us to rapidly build and strengthen our drug development organization.”